达帕格利弗洛辛在患有HFrEF的住院患者的利尿作用和功能影响
Shanshan Li1, Youxuan Wu2, Xiaolei Hu2
1Phase I Clinical Trial Research Center, Xiangya Hospital, Central South University, Changsha 410008. 228112398@csu.edu.cn.
概括
在住院的心力衰竭患者中,达帕格利弗洛辛增强了尿液和减少了NT-proBNP. 这种SGLT2抑制剂在患有功能障碍的人群中显示出较轻的eGFR下降,并且具有优越的短期成本效益.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 心力衰竭与减少喷射分数 (HFrEF) 的管理通常涉及尿剂的液体过载.
- 达帕格利弗洛辛在改善住院HFrEF患者的利尿疗效和结局方面的作用需要进一步调查.
研究的目的:
- 评估达帕格利弗洛辛对HFrEF住院患者的利尿和功能的影响.
- 为了比较达帕格利弗洛辛和标准治疗之间的利尿疗效,功能变化和成本效益.
主要方法:
- 对200名住院的HFrEF患者进行了回顾性分析.
- 标准治疗组 (n=120) 与达帕格利弗洛辛治疗组 (n=80) 的比较.
- 评估液体平衡,尿液输出,利尿效率,EGFR,NT-proBNP和成本效益.
主要成果:
- 达帕格利弗洛辛组显示出显著更高的液体摄入量-输出差异,尿液输出和利尿效率.
- 在达帕格利弗洛辛组中观察到较轻的eGFR下降,用于功能受损的患者.
- 在达帕格利弗洛辛组,NT-proBNP水平下降得更显著.
结论:
- 在住院的HFrEF患者中,达帕格利弗洛辛增强尿液和减少NT-proBNP.
- 达帕格利弗洛辛 (Dapagliflozin) 证明对功能有保护作用,特别是在先前存在功能障碍的患者中.
- 与标准治疗相比,达帕格利弗洛辛具有优越的短期成本效益概况.
相关概念视频
Heart Failure Drugs: Diuretics
298
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
Factors Affecting Renal Clearance: Renal Impairment
37
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
37
Renal Failure: Dose Adjustments
46
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
46
Dipeptidyl Peptidase 4 Inhibitors
142
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
142
Antihypertensive Drugs: Action of Diuretics
590
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
590
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
334
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
334


